Ebglyss/Lebrikizumab
Moderate-to-Severe Atopic Dermatitis
Key Facts
Indication
Moderate-to-Severe Atopic Dermatitis
Phase
Marketed/Registration
Status
Launched in EU; Under Review in US
Company
About Almirall
Almirall is a publicly traded, revenue-generating pharmaceutical company with a singular strategic focus on becoming a global leader in medical dermatology. The company has successfully transformed from a broad-based pharma player into a specialized dermatology entity, leveraging deep internal R&D, strategic partnerships, and a direct commercial infrastructure. Its mission is to deliver innovative science to improve the lives of patients with skin conditions, supported by a growing portfolio of marketed products and a promising clinical pipeline.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Regulatory Review |
| Amlitelimab | Sanofi | Phase 3 |
| Zumilokibart (APG777) | Apogee Therapeutics | Phase 2 |
| APG279 (Zumilokibart + APG990) | Apogee Therapeutics | Phase 1 |
| IDgenix (AdvanceAD Tx) | Castle Biosciences | Commercial/Early Launch |
| Rademikibart (CBP-201) | Connect Biopharma | Phase 3 |